Genprex cancer gene therapy paired with AZ, Merck lung cancer drugsAn experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Share XGenprex cancer gene therapy paired with AZ, Merck lung cancer drugshttps://pharmaphorum.com/news/genprex-cancer-gene-therapy-paired-with-az-merck-lung-cancer-drugs/
FDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancerThe FDA has granted a fast review for AstraZeneca’s Tagrisso oncology drug in certain patients with early-stage lung Share XFDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancerhttps://pharmaphorum.com/news/fda-grants-fast-review-for-astrazenecas-tagrisso-in-early-stage-lung-cancer/
Price cut wins NICE OK for AZ’s Tagrisso in untreated lung cancerUK cost-effectiveness watchdog NICE has changed its stance on AstraZeneca’s Tagrisso as a first-line therapy for non-small cell Share XPrice cut wins NICE OK for AZ’s Tagrisso in untreated lung cancerhttps://pharmaphorum.com/news/price-cut-wins-nice-ok-for-azs-tagrisso-in-untreated-lung-cancer/
ASCO 2020 round-up: Virtual conference still delivers the dramaASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping Share XASCO 2020 round-up: Virtual conference still delivers the dramahttps://pharmaphorum.com/views-analysis-oncology/asco-2020-round-up-virtual-conference-still-delivers-the-drama/
Given after surgery, AZ’s Tagrisso prevents lung cancer coming backAstraZeneca opened its account at this year’ virtual ASCO meeting with data showing that adjuvant (post-surgery) use of Share XGiven after surgery, AZ’s Tagrisso prevents lung cancer coming backhttps://pharmaphorum.com/news/given-after-surgery-azs-tagrisso-prevents-lung-cancer-coming-back/
Tagrisso trial halted early after ‘overwhelming’ efficacyA phase III trial for AstraZeneca’s lung cancer drug Tagrisso (osimertinib) will be unblinded early after strong results. Share XTagrisso trial halted early after ‘overwhelming’ efficacyhttps://pharmaphorum.com/news/tagrisso-trial-halted-early-after-overwhelming-efficacy/
AZ’s new cancer drugs drive another stellar quarterAstraZeneca has raised its sales guidance of the year once again as its trio of new cancer drugs Share XAZ’s new cancer drugs drive another stellar quarterhttps://pharmaphorum.com/news/azs-new-cancer-drugs-drive-another-stellar-quarter/
AZ gets China nod for Tagrisso in first-line lung cancerAstraZeneca has scored another approval for one of its new drugs in China, this time getting a green Share XAZ gets China nod for Tagrisso in first-line lung cancerhttps://pharmaphorum.com/news/az-gets-china-nod-for-tagrisso-in-first-line-lung-cancer/
AstraZeneca gets further approval for Tagrisso in JapanAstraZeneca received approval from the Japanese regulator following a priority review of Tagrisso (osimertinib) as a first-line treatment Share XAstraZeneca gets further approval for Tagrisso in Japanhttps://pharmaphorum.com/news/astrazeneca-tagrisso-approval/
